



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁴ : C12N 15/00, 5/00, C12P 21/00	A1	(11) International Publication Number: WO 89/01036 (43) International Publication Date: 9 February 1989 (09.02.89)
<p>(21) International Application Number: PCT/GB88/00602</p> <p>(22) International Filing Date: 22 July 1988 (22.07.88)</p> <p>(31) Priority Application Number: 8717430</p> <p>(32) Priority Date: 23 July 1987 (23.07.87)</p> <p>(33) Priority Country: GB</p> <p>(71) Applicant (for all designated States except US): CELL-TECH LIMITED [GB/GB]; 216 Bath Road, Slough, Berkshire SL1 4EN (GB).</p> <p>(72) Inventor; and (75) Inventor/Applicant (for US only): BEBBINGTON, Christopher, Robert [GB/GB]; 20C Trinity Place, Windsor, Berkshire SL4 3AT (GB).</p> <p>(74) Agent: VOTIER, Sidney, David; Carpmaels & Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB).</p>		<p>(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US.</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: RECOMBINANT DNA EXPRESSION VECTORS</p> <div data-bbox="394 1108 1234 1745"> </div> <p>(57) Abstract</p> <p>The invention provides expression vectors containing the promoter, enhancer and substantially complete 5'-untranslated region including the first intron of the major immediate early gene of human cytomegalovirus. Further vectors including the hCMV-MIE DNA linked directly to the coding sequence of a heterologous gene are described. Host cells transfected with the vectors and a process for producing heterologous polypeptides using the vectors and the use of the hCMV-MIE DNA for expression of a heterologous gene are also included within the invention.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

RECOMBINANT DNA EXPRESSION VECTORSField of the Invention

5 This invention relates to expression vectors containing a DNA sequence from the human cytomegalovirus major immediate early gene, to host cells containing such vectors, to a method of producing a desired polypeptide by using vectors containing said sequence and to the use of said DNA sequence.

Background to the Invention

10 The main aim of workers in the field of recombinant DNA technology is to achieve as high a level of production as possible of a particular polypeptide. This is particularly true of commercial organisations who wish to exploit the use of recombinant DNA technology to produce polypeptides which naturally are not very abundant.

15 Generally the application of DNA technology involves the cloning of a gene encoding the desired polypeptide, placing the cloned gene in a suitable expression vector, transfecting a host cell line with the vector, and culturing the transfected cell line to produce the polypeptide. It is almost impossible to predict whether any
20 particular vector or cell line or combination thereof will lead to a useful level of production.

In general, the factors which significantly affect the amount of polypeptide produced by a transfected cell line are: 1. gene copy number, 2. efficiency with which the gene is transcribed and the
25 mRNA translated, 3. the stability of the mRNA and 4. the efficiency of secretion of the protein.

The majority of work directed at increasing expression levels of recombinant polypeptides has focussed on improving transcription initiation mechanisms. As a result the factors affecting efficient
30 translation are much less well understood and defined, and generally it is not possible to predict whether any particular DNA sequences will be of use in obtaining efficient translation.

Attempts at investigating translation have consisted largely of varying the DNA sequence around the consensus translation start signal to determine what effect this has on translation initiation (Kozak M. Cell 41 283-292 (1986)).

5 Studies involving expression of desired heterologous genes normally use both the coding sequence and at least part of the 5'-untranslated sequence of the heterologous gene such that translation initiation is from the natural sequence of the gene. This approach has been found to be unreliable probably as a result
10 of the 'hybrid nature' of the 5'-untranslated region and the fact that the presence of particular 5-untranslated sequences can lead to poor initiation of translation (Kozak M. Procl. Natl. Acad. Sci. 83 2850-2854 (1986) and Pelletier and Sonenberg Cell 40 515-526 (1985)). This variation in translation has a detrimental effect on
15 the amount of the product produced.

Previous studies (Boshart et al Cell 41 521-530 (1985) and Pasleau et al, Gene 38 227-232 (1985); Stenberg et al, J. Virol 49 (1) 190-199 (1984); Thomsen et al Proc. Natl. Acad. Sci. USA 81 659-663 (1984) and Foecking and Hofstetter Gene 45 101-105 (1986)) have used
20 sequences from the upstream region of the hCMV-MIE gene in expression vectors. These have, however, solely been concerned with the use of the sequences as promoters and/or enhancers. Spaete and Mocarski (J. Virol 56 (1) 135-143, 1985) have used a PstI to PstI
25 fragment of the hCMV-MIE gene encompassing the promoter, enhancer and part of the 5'-untranslated region, as a promoter for expression of heterologous genes. In order to obtain translation the natural 5'-untranslated region of the heterologous gene was used.

In published European Patent Application No. 260148, a method for the continuous production of a heterologous protein is described.
30 The expression vectors constructed contain part of the 5'-untranslated region of the hCMV-MIE gene as a stabilising

sequence. The stabilising sequence is placed in the 5'-untranslated region of the gene encoding the desired heterologous protein i.e. the teaching is again that the natural 5'-untranslated region of the gene is essential for translation.

5 Summary of the Invention

In a first aspect the invention provides a vector containing a DNA sequence comprising the promoter, enhancer and substantially complete 5'-untranslated region including the first intron of the major immediate early gene of human cytomegalovirus.

10 In a preferred embodiment of the first aspect of the invention, the vector includes a restriction site for insertion of a heterologous gene.

The present invention is based on the discovery that vectors containing a DNA sequence comprising the promoter, enhancer and complete 5'-untranslated region of the major immediate early gene of the human cytomegalovirus (hCMV-MIE) upstream of a heterologous gene result in high level expression of the heterologous gene product. In particular, we have unexpectedly found that when the hCMV-MIE derived DNA is linked directly to the coding sequence of the heterologous gene high levels of mRNA translation are achieved. This efficient translation of mRNA is achieved consistently and appears to be independent of the particular heterologous gene being expressed.

25 In a second aspect the invention provides a vector containing a DNA sequence comprising the promoter, enhancer and substantially complete 5'-untranslated region including the first intron of the major immediate early gene of human cytomegalovirus upstream of a heterologous gene.

30 The hCMV-MIE derived DNA according to the second aspect of the invention may be separated from the coding sequence of the

heterologous gene by intervening DNA such as for example by the 5'-untranslated region of the heterologous gene. Advantageously the hCMV-MIE derived DNA may be linked directly to the coding sequence of the heterologous gene.

5 In a preferred embodiment of the second aspect of the invention, the invention provides a vector containing a DNA sequence comprising the promoter, enhancer and substantially complete 5'-untranslated region including the first intron of the hCMV-MIE gene linked directly to the DNA coding sequence of the heterologous gene.

10 Preferably the hCMV-MIE derived sequence includes a sequence identical to the natural hCMV-MIE translation initiation signal. It may however be necessary or convenient to modify the natural translation initiation signal to facilitate linking the coding sequence of the desired polypeptide to the hCMV-MIE sequence, i.e.
15 by introducing a convenient restriction enzyme recognition site. For example the translation initiation site may advantageously be modified to provide an NcoI recognition site.

The heterologous gene may be a gene coding for any eukaryotic polypeptide such as for example a mammalian polypeptide such as an
20 enzyme, e.g. chymosin or gastric lipase; an enzyme inhibitor, e.g. tissue inhibitor of metalloproteinase (TIMP); a hormone, e.g. growth hormone; a lymphokine, e.g. an interferon; a plasminogen activator, e.g. tissue plasminogen activator (tPA) or prourokinase; or a natural, modified or chimeric immunoglobulin or a fragment thereof
25 including chimeric immunoglobulins having dual activity such as antibody-enzyme or antibody-toxin chimeras.

According to a third aspect of the invention there is provided host cells transfected with vectors according to the first or second aspect of the invention.

The host cell may be any eukaryotic cell such as for example plant, or insect cells but is preferably a mammalian cell such as for example CHO cells or cells of myeloid origin e.g. myeloma or hybridoma cells.

5 In a fourth aspect the invention provides a process for the production of a heterologous polypeptide by culturing a transfected cell according to the third aspect of the invention.

10 In a fifth aspect the invention provides the use of a DNA sequence comprising the promoter, enhancer and substantially complete 5'-untranslated region including the first intron of the hCMV-MIE gene for expression a heterologous gene.

In a preferred embodiment of the fifth aspect of the invention the hCMV-MIE derived DNA sequence is linked directly to the DNA coding sequence of the heterologous gene.

15 Also included within the scope of the invention are plasmids pCMGS, pHT.1 and pEE6hCMV.

Brief Description of the Drawings

The present invention is now described, by way of example only, with reference to the accompanying drawings in which

- 20 Figure 1: shows a diagrammatic representation of plasmid pSVLGS.1
Figure 2: shows a diagrammatic representation of plasmid pHT.1
Figure 3: shows a diagrammatic representation of plasmid pCMGS
Figure 4: shows the complete sequence of the promoter-enhancer hCMV-MIE including both the first intron and a modified translation 'start' site
25 Figure 5: shows a diagrammatic representation of plasmid pEE6.hCMV

Detailed Description of the EmbodimentsExample 1

The Pst-1m fragment of hCMV (Boshart *et al* Cell 41 521-530 (1985) Spaete & Mocarski J. Virol 56 (1) 135-143 (1985)) contains the promoter-enhancer and most of the 5'-untranslated leader of the MIE gene including the first intron. The remainder of the 5'untranslated sequence can be recreated by attaching a small additional sequence of approximately 20 base pairs.

Many eukaryotic genes contain an NcoI restriction site (5'-CCATGG-3') overlapping the translation start site, since this sequence frequently forms part of a preferred translation initiation signal 5'ACCATGPu-3'. The hCMV-MIE gene does not have an NcoI site at the beginning of the protein coding sequence but a single base-pair alteration causes the sequence both to resemble more closely the "Kozak" consensus initiation signal and introduces an NcoI recognition site. Therefore a pair of complementary oligonucleotides were synthesised of the sequence:

```

      GTCACCGTCCTTGACAC
      |||||
ACGTCAGTGGCAGGAACGTGGTAC

```

which when fused to the Pst-1m fragment of hCMV will recreate the complete 5'-untranslated sequence of the MIE gene with the single alteration of a G to a C at position -1 relative to the translation initiation codon.

This synthetic DNA fragment was introduced between the hCMV Pst-1m promoter-enhancer leader fragment and a glutamine synthetase (GS) coding sequence by ligation of the Pst-1m fragment and the synthetic oligomer with NcoI digested pSV2.GS to generate a new plasmid, pCMGS (The production of pSV2.GS is described in published International Patent Application No. WO 8704462). pCMGS is shown in Figure 3. pCMGS thus contains a hybrid transcription unit consisting of the following: the synthetic oligomer described above upstream of the

hCMV-MIE promoter-enhancer (where it serves merely as a convenient PstI - NcoI "adaptor"), the hCMV-MIE promoter and the complete 5' untranslated region of the MIE gene, including the first intron, fused directly to the GS coding sequence at the translation initiation site.

pCMGS was introduced into CHO-KI cells by calcium phosphate mediated transfection and the plasmid was tested for the ability to confer resistance to the GS-inhibitor methionine sulfoximine (MSX). The results of a comparison with pSV2.GS are shown in Table 1.

It is clear that pCMGS can confer resistance to 20 M MSX at a similar frequency to pSV2.GS, demonstrating that active GS enzyme is indeed expressed in this vector.

Table 1

Results of transfection of GS-expression vectors into CHO-KI cells

15	<u>Vector</u>	<u>no. colonies/10⁶ cells</u>
		<u>resistant to 20µM MSX</u>
	pSV2.GS	32
	pCMGS	17
	Control	0

20 Example 2

The TIMP cDNA and SV40 polyadenylation signal as used in pTIMP 1 Docherty et al (1985) Nature 318, 66-69, was inserted into pEE6 between the unique HindIII and BamHI sites to create pEE6TIMP. pEE6 is a bacterial vector from which sequences inhibitory to replication in mammalian cells have been removed. It contains the XmnI to BclI portion of pCT54 (Emtage et al 1983 Proc. Natl. Acad. Sci. USA 80,

3671-3675) with a pSP64 (Melton et al 1984: Nucleic Acids. Res. 12, 7035) polylinker inserted in between the HindIII and EcoRI sites. The BamHI and SalI sites have been removed from the polylinker by digestion, filling in with Klenow enzyme and religation. The BclI to BamHI fragment is a 237 bp SV40 early polyadenylation signal (SV40 2770 to 2533). The BamHI to the BglI fragment is derived from pBR328 (375 to 2422) with an additional deletion between the SalI and the AvaI sites (651 to 1425) following the addition of a SalI linker to the AvaI site. The sequence from the BglI to the XmnI site originates from the β -lactamase gene of pSP64.

The 2129 base-pair NcoI fragment containing the hCMV MIE promoter-enhancer and 5' untranslated sequence was isolated from pCMGS by partial NcoI digestion and inserted at the NcoI site overlapping the translation initiation signal of TIMP in pEE6.TIMP to generate the plasmid pHT.1 (shown in Figure 2).

A GS gene was introduced into pHT.1 to allow selection of permanent cell lines by introducing the 5.5K PvuI - BamHI fragment of pSVLGS.1 (figure 1) at the BamHI site of pHT.1 after addition of a synthetic BamHI linker to PvuI digested pSVLGS.1 to form pHT.1GS. In this plasmid the hCMV-TIMP and GS transcription units transcribe in the same orientation.

pHT.1 GS was introduced into CHO-K1 cells by calcium-phosphate mediated transfection and clones resistant to 20 μ M MSX were isolated 2-3 weeks post-transfection. TIMP secretion rates were determined by testing culture supernatants in a specific two site ELISA, based on a sheep anti TIMP polyclonal antibody as a capture antibody, a mouse TIMP monoclonal as the recognition antibody, binding of the monoclonal being revealed using a sheep anti mouse IgG peroxidase conjugate. Purified natural TIMP was used as a standard for calibration of the assay and all curves were linear in the range of 2 - 20ng ml⁻¹. No non-specific reaction was detectable in CHO-cell conditioned culture media.

One cell line GS.19 was subsequently recloned, and a sub-clone GS 19-12 secretes TIMP at a very high level of 3×10^8 molecules/cell/day. Total genomic DNA extracted from this cell line was hybridised with a TIMP probe by Southern blot analysis using standard techniques and shown to contain a single intact copy of the TIMP transcription unit per cell (as well as two re-arranged plasmid bands). This cell line was selected for resistance to higher levels of MSX and in the first selection a pool of cells resistant to 500 μ M MSX was isolated and recloned. The clone GS-19.6(500)14 secretes 3×10^9 molecules TIMP/cell/day. The vector copy-number in this cell line is approx. 20 - 30 copies/cell. Subsequent rounds of selection for further gene amplification did not led to increased TIMP secretion.

Thus it appears that the hCMV-TIMP transcription unit from pHT.1 can be very efficiently expressed in CHO-KI cells at approximately a single copy per cell and a single round of gene amplification leads to secretion rates which are maximal using current methods.

Example 3

In order to test whether the hCMV-MIE promoter-enhancer-leader can be used to direct the efficient expression of other protein sequences, two different but related plasminogen activator coding sequences (designated PA-1 and PA-2) were introduced into CHO-KI cells in vectors in which the protein coding sequences were fused directly to the hCMV sequence.

In both these cases, there is no NcoI site at the beginning of the translated sequence and so synthetic oligonucleotides were used to recreate the authentic coding sequence from suitable restriction sites within the translated region. The sequence of the modified hCMV translation-initiation signal as used in pHT.1 was also built into the synthetic oligonucleotide which then ended in a Pst-I restriction site. The Pst-I μ m fragment of hCMV was then inserted at this site to create the complete promoter-enhancer-leader sequence.

The hCMV-plasminogen activator transcription units were introduced into CHO-KI cells after inserting a GS gene at the unique BamHI site as above and MSX resistant cell lines secreting plasminogen activator were isolated.

- 5 The secretion rates of the best initial transfectant cell lines in each case are given in Table 2. From this it is clear that the hCMV promoter-enhancer leader can also be used to direct the efficient expression of these two plasminogen activator proteins.

Table 2

- 10 Secretion rates of the different plasminogen activator proteins from transfectant CHO cell lines.

<u>Plasminogen activator</u>	<u>Molecules secreted/cell/day</u>
PA - 1	5.5×10^7
PA - 2	1.1×10^8

- 15 Example 4

pEE6hCMV was made by ligating the Pst-I_m fragment of hCMV, HindIII - digested pEE6 and the complementary oligonucleotides of the sequence:

```
      GTCACCGTCCTTGACACGA
      ||| ||| ||| ||| ||| |||
ACGTCAGTGGCAGGAAGTGTGCTCGA
```

- 20 cDNA encoding an immunoglobulin light-chain was inserted at the EcoRI site of pEE6.hCMV such that the hCMV-MIE promoter-enhancer leader could direct expression of the cDNA and a selectable marker gene containing the SV40 origin of replication was inserted at the BamHI site of each plasmid.

5 This plasmid was transfected into COS-1 monkey kidney cells by a standard DEAE-dextran transfection procedure and transient expression was monitored 72 hours post transfection. Light chain was secreted into the medium at at least 100ng/ml indicating that light chain can indeed be expressed from a transcription unit containing the entire hCMV-MIE 5'-untranslated sequence up to but not including the translation initiation ATG, followed by 15 bases of natural 5'-untranslated sequence of the mouse immunoglobulin light-chain gene.

CLAIMS

1. A vector containing a DNA sequence comprising the promoter, enhancer and substantially complete 5'-untranslated region including the first intron of the hCMV-MIE gene.
- 5 2. A vector according to claim 1 wherein the vector includes a restriction site for insertion of a heterologous gene.
3. A vector containing a DNA sequence comprising the promoter, enhancer and substantially complete 5'-untranslated region including the first intron of the hCMV-MIE gene upstream of a heterologous gene.
- 10 4. A vector according to Claim 3 wherein the hCMV-MIE DNA is linked directly to the DNA coding sequence of a heterologous gene.
5. A vector according to Claim 4 wherein the hCMV-MIE DNA includes a translation initiation signal.
- 15 6. A host cell transfected with a vector according to any of the preceeding claims.
7. A process for the production of a heterologous polypeptide by culturing a host cell according to Claim 6.
- 20 8. The use of a DNA sequence comprising the promoter, enhancer and substantially complete 5'-untranslated region including the first intron of the hCMV-MIE gene for expression of a heterologous gene.
9. The use of a DNA sequence according to Claim 8 wherein the hCMV-MIE derived DNA is linked directly to the coding sequence of the heterologous gene.
- 25 10. Plasmids pCMGS, pEE6.hCMV and pHT.1

1/9




Fig. 1




Fig. 2

3/9

DNS			T	
sct		p	t	AM
aox		s	h	fl
111		t	3	lu
//		1	2	31
				/

1 CCATGGTGTCAAGGACGGTGACTGCAGTGAATAATAAAATGTGTGTTTGTCCGAAATACG 60
 -----+-----+-----+-----+-----+-----+
 GGTACCACAGTTCTGCTGCACTGACGTCACTTATTATTTTACACACAAACAGGCTTTATGC
 CGTTTTGAGATTTCTGTGCGCCGACTAAATTCATGTGCGCGGATAGTGGTGTTCATCGCCG 120
 -----+-----+-----+-----+-----+-----+
 61 GCAAACTCTAAAGACAGCGGCTGATTTAAGTACAGCGCGCTATCACCACAAATAGCGGC

C
l
a
1

121 ATAGAGATGGCGATATTGGAATAATCGATATTTGAAAAATATGGCATATTGAAAAATGTGCG 180
 -----+-----+-----+-----+-----+-----+
 TATCTCTACCGCTATAACCTTTTTAGCTATAAACTTTTATACCGTATAACTTTTACAGCG

E
c
o
r
v

181 CGATGTGAGTTTCTGTGTAAGTATCGCCATTTTTCCAAAAGTGATTTTTGGGCATAC 240
 -----+-----+-----+-----+-----+-----+
 GCTACACTCAAAGACACATTGACTATAGCGGTAAAAAGGTTTCACTAAAAACCCGTATG

E
c
o
r
v

241 GCGATATCTGGCGATAGCGGCTTATATCGTTTACGGGGGATGGCGATAGACGACTTTGGT 300
 -----+-----+-----+-----+-----+-----+
 CGCTATAGACCGCTATCGCCGAATATAGCAAATGCCCCCTACCGCTATCTGCTGAAACCA
 GACTTGGGCGATTCTGTGTGTCGCAATATCGCAGTTTTCGATATAGGTGACAGACGATAT 360
 -----+-----+-----+-----+-----+-----+
 301 CTGAACCCGCTAAGACACACAGCGTTTATAGCGTCAAAGCTATATCCACTGTCTGCTATA

	C BH	N C
	f aa	s l
	r le	i a
	1 11	1 1
		/

361 GAGGCTATATCGCCGATAGAGGCGACATCAAGCTGGCACATGGCCAATGCATATCGATCT 420
 -----+-----+-----+-----+-----+-----+
 CTCCGATATAGCGGCTATCTCCGCTGTAGTTCGACCGGTACCGGTTACGTATAGCTAGA

Fig. 4A

4/9

S C BH
s f aa
p r le
1 1 11
/

421 ATACATTGAATCAATATTGGCCATTAGCCATATTATTCATTGGTTATATAGCATAAATCA 480
-----+-----+-----+-----+-----+-----+
TATGTAACCTTAGTTATAACCGGTAATCGGTATAATAAGTAACCAATATATCGTATTTAGT
S C BH
s f aa
p r le
1 1 11
/

481 ATATTGGCTATTGGCCATTGCATACGTTGTATCCATATCATAATATGTACATTTATATTG 540
-----+-----+-----+-----+-----+-----+
TATAACCGATAACCGGTAACGTATGCAACATAGGTATAGTATTATACATGTAAATATAAC

H M S
i m p
n m e
c e e
2 1 1

541 GTCATGTCCAACATTACCGCCATGTTGACATTGATTATTGACTAGTTATTAATAGTAAT 600
-----+-----+-----+-----+-----+-----+
CGAGTACAGGTTGTAATGGCGGTACAACGTGTAACATAAAGTATCAATAATTATCATTA
CAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCGCGGTTACATAACTTACGG
601 -----+-----+-----+-----+-----+-----+ 660
GTTAATGCCCCAGTAATCAAGTATCGGGTATATACCTCAAGGCGCAATGTATTGAATGCC

B A A
g h a
l a t
1 2 2

661 TAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCGCCCATTTGACGTCAATAATGACGT 720
-----+-----+-----+-----+-----+-----+
ATTTACCGGGCGGACCGACTGGCGGGTTGCTGGGGGCGGGTAACTGCAGTTATTACTGCA

A A
h a
a t
2 2

721 ATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTAC 780
-----+-----+-----+-----+-----+-----+
TACAAGGTATCATTGCGGTTATCCCTGAAAGGTAAGTGCAGTTACCCACCTCATAAATG

B N
g d
l e
1 1

781 GGTAAGTGGCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTG 840
-----+-----+-----+-----+-----+-----+
CCATTTGACGGGTGAACCGTCATGTAGTTCACATAGTATACGGTTCATGCGGGGGATAAC

Fig. 4 B

5/9

A	A	B
h	a	g
a	t	l
2	2	1

841 ACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCAGTACATGACCTTATGGGACT
 -----+-----+-----+-----+-----+-----+-----+ 900
 TGCAGTTACTGCCATTTACCGGGCGGACCGTAATACGGGTCATGTACTGGAATACCCTGA

S	DNS
n	sct
a	aoy
B	111
1	//

901 TTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTT
 -----+-----+-----+-----+-----+-----+ 960
 AAGGATGAACCGTCATGTAGATGCATAATCAGTAGCGATAATGGTACCACTACGCCAAAA
 GGCAGTACATCAATGGGCGTGGATAGCGGTTTGA CTACGCGGATTTC CAAGTCTCCACC
 961 -----+-----+-----+-----+-----+-----+ 1020
 CCGTCATGTAGTTACCCGCACCTATCGCCAAACTGAGTGCCCTAAAGGTTTCAGAGGTGG

A	A	B
h	a	a
a	t	n
2	2	1

1021 CCATTGACGTCAATGGGAGTTTGT TTTGGCACCAAAATCAACGGGACTTTCCAAAATGTC
 -----+-----+-----+-----+-----+-----+ 1080
 GGTAAC TGCA GTTACCCTCAAACAAAACCGTG GTTTTAGTTGCCCTGAAAGGTTTTACAG
 GTAACAAC TCCGCCCCATTGACGCAAA TGGGCGGTAGGCGTG TACGGTGGGAGGTCTATA
 1081 -----+-----+-----+-----+-----+-----+ 1140
 CATTGTTGAGGCGGGGTAAC TGCGTTTACCCGCCATCCGCACATGCCACCCTCCAGATAT

BH	G	A
BssS	s	h
apia	u	a
n1Ac	1	2
2211		
///		

1141 TAAGCAGAGCTCGTTTAGTGAACCGTCAGATCGCCTGGAGACGCCATCCACGCTGTTTTG
 -----+-----+-----+-----+-----+-----+ 1200
 ATTCTCTCGAGCAAATCACTTGGCAGTCTAGCGGACCTCTGCGGTAGGTGCGACAAAAC

B	N
b	D BCGsSX
v	s gfdpam
2	a lriBca
	1 112223
	////

1201 ACCTCCATAGAAGACACCGGGACCGATCCAGCCTCCGCGGCCGGAACGGTGCATTGGAA
 -----+-----+-----+-----+-----+-----+ 1260
 TGGAGGTATCTTCTGTGGCCCTGGCTAGGTGCGAGGCGCCGCCCTTGCCACGTAACCTT

Fig. 4C

6/9

CGCGGATTCCCCGTGCCAAGAGTGACGTAAGTACCGCCTATAGAGTCTATAGGCCACCC
 1261-----+-----+-----+-----+-----+ 1320
 GCGCCTAAGGGGCACGGTTCTCACTGCATTTCATGGCGGATATCTCAGATATCCGGGTGGG

B N
 Ss N ss
 tt s pp
 yX i Hh
 11 1 11
 /

CCTTGGCTTCTTATGCATGCTATACTGTTTTTGGCTTGGGGTCTATACACCCCCGCTTCC
 1321-----+-----+-----+-----+-----+ 1380
 GGAACCGAAGAATACGTACGATATGACAAAACCGAACCCAGATATGTGGGGGCGAAGG

E
 S
 P
 1

TCATGTTATAGGTGATGGTATAGCTTAGCCTATAGGTGTGGGTATTGACCATTATTGAC
 1381-----+-----+-----+-----+-----+ 1440
 AGTACAATATCCACTACCATATCGAATCGGATATCCACACCCAATAACTGGTAATAACTG

P
 f
 l
 M
 1

CACTCCCTATTGGTGACGATACTTTCCATTACTAATCCATAACATGGCTCTTTGCCACA
 1441-----+-----+-----+-----+-----+ 1500
 GTGAGGGGATAACCACTGCTATGAAAGGTAATGATTAGGTATTGTACCGAGAAACGGTGT

E
 C
 O
 5
 7

ACTCTCTTTATTGGCTATATGCCAATACACTGTCCTTCAGAGACTGACACGGACTCTGTA
 1501-----+-----+-----+-----+-----+ 1560
 TGAGAGAAATAACCGATATACGGTTATGTGACAGGAAGTCTCTGACTGTGCCTGAGACAT

E
 C
 O
 3
 1

TTTTACAGGATGGGGTCTCATTTATTATTTACAAATTCACATATACAACACCACCGTCC
 1561-----+-----+-----+-----+-----+ 1620
 AAAAATGTCCTACCCCAGAGTAAATAATAAATGTTTAAGTGTATATGTTGTGGTGGCAGG

B X A A
 s h v f
 p o a 1
 1 2 1 3
 2

CCAGTGCCCGCAGTTTTTATTAAACATAACGTGGGATCTCCACGCGAATCTCGGGTACGT
 1621-----+-----+-----+-----+-----+ 1680
 GGTCACGGGCGTCAAAAATAATTGTATTGCACCCTAGAGGTGCGCTTAGAGCCCATGCA

Fig. 4D

7/9

B s p M 2	B Bs ap n1 22 /	B Bs ap n1 22 /
-----------------------	--------------------------------	--------------------------------

1681-----+-----+-----+-----+-----+-----+ 1740
 GTTCCGGACATGGGCTCTTCTCCGGTAGCGGCGGAGCTTCTACATCCGAGCCCTGCTCCC
 CAAGGCCTGTACCCGAGAAGAGGCCATCGCCGCCTCGAAGATGTAGGCTCGGGACGAGGG

G s u 1	H a e 1
------------------	------------------

1741-----+-----+-----+-----+-----+-----+ 1800
 ATGCCTCCAGCGACTCATGGTCGCTCGGCAGCTCCTTGCTCCTAACAGTGGAGGCCAGAC
 TACGGAGGTCGCTGAGTACCAGCGAGCCGTCGAGGAACGAGGATTGTCACCTCCGGTCTG

D s a 1

1801-----+-----+-----+-----+-----+-----+ 1860
 TTAGGCACAGCACGATGCCCACCACCACAGTGTGCCGCACAAGGCCGTGGCGGTAGGGT
 AATCCGTGTCGTGCTACGGGTGGTGGTGGTCACACGGCGTGTTCCGGCACCGCCATCCCA

BH ABsgS vapia an1Ac 12211 ///	N s p B 2	A B f b l v 2 2
---	-----------------------	--------------------------

1861-----+-----+-----+-----+-----+-----+ 1920
 ATGTGTCTGAAAATGAGCTCGGGGAGCGGGCTTGCACCGCTGACGCATTTGGAAGACTTA
 TACACAGACTTTTACTCGAGCCCTCGCCCGAACGTGGCGACTGCGTAAACCTTCTGAAT

N s p B 2	N sP pv Bu 22 /
-----------------------	--------------------------------

1921-----+-----+-----+-----+-----+-----+ 1980
 AGGCAGCGGCAGAAGAAGATGCAGGCAGCTGAGTTGTTGTGTTCTGATAAGAGTCAGAGG
 TCCGTGCGCGTCTTCTTCTACGTCCGTGCGACTCAACAACACAAGACTATTCTCAGTCTCC

H iH np ca 21 /	S c a 1
--------------------------------	------------------

1981-----+-----+-----+-----+-----+-----+ 2040
 TAACTCCCGTTGCGGTGCTGTAAACGGTGGAGGGCAGTGTAGTCTGAGCAGTACTCGTTS
 ATTGAGGGCAACGCCACGACAATTGCCACCTCCCGTCACATCAGACTCGTCATGAGCAAC

Fig. 4E

SUBSTITUTE SHEET

8/9

```

      B B
      S S
      S S
      H H
      2 2

                                DNS
                                sct
                                aoy
                                111
                                //
2041-----+-----+-----+-----+-----+-----+ 2100
      CTGCCGCGCGCGCCACCAGACATAATAGCTGACAGACTAACAGACTGTTTCCTTTCCATGG
      GACGGCGCGCGCGGTGGTCTGTATTATCGACTGTCTGATTGTCTGACAAGGAAAGGTACC

      P      DNS
      S      sct
      t      aoy
      1      111
              // NcoI
2101-----+-----+-----+-----+-----+
      GTCTTTTCTGCAGTCACCGTCCTTGACACCATG
      CAGAAAAGACGTCAGTGGCAGGAAGTGTG
```

Fig.4F

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 88/00602

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁸ According to International Patent Classification (IPC) or to both National Classification and IPC IPC ⁴ : C 12 N 15/00; C 12 N 5/00; C 12 P 21/00																	
II. FIELDS SEARCHED <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Minimum Documentation Searched ⁷</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 30%; text-align: left; border-bottom: 1px solid black;">Classification System</th> <th style="text-align: left; border-bottom: 1px solid black;">Classification Symbols</th> </tr> <tr> <td style="border-right: 1px solid black; padding: 5px;">IPC⁴</td> <td style="padding: 5px;">C 12 N; C 12 P</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁶</div>			Classification System	Classification Symbols	IPC ⁴	C 12 N; C 12 P											
Classification System	Classification Symbols																
IPC ⁴	C 12 N; C 12 P																
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁵ <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; text-align: left; border-bottom: 1px solid black;">Category ⁹</th> <th style="text-align: left; border-bottom: 1px solid black;">Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th style="width: 10%; text-align: left; border-bottom: 1px solid black;">Relevant to Claim No. ¹³</th> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;">EP, A, 0173177 (BEHRINGWERKE AG) 5 March 1986 see the whole document --</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-9</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;">EP, A, 0173552 (THE UPJOHN CO.) 5 March 1986 see page 9, line 25 - page 10, line 2 --</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-9</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;">Gene, vol. 38, no. 1/3, 1985 Elsevier Biomedical Press, (Amsterdam, NL) F. Pasleau et al.: "Growth hormone gene expression in eukaryotic cells directed by the Rous sarcoma virus long terminal repeat or cytomegalovirus immediate- early promoter"; pages 227-232; see page 228, second column --</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-9</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;">Journal of Virology, vol. 56, no. 1, October 1985 American Society for Microbiology (US) R.R. Spaete et al.: "Regulation of cytomegalovirus gene expression: α and β</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-9</td> </tr> </table>			Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X	EP, A, 0173177 (BEHRINGWERKE AG) 5 March 1986 see the whole document --	1-9	X	EP, A, 0173552 (THE UPJOHN CO.) 5 March 1986 see page 9, line 25 - page 10, line 2 --	1-9	X	Gene, vol. 38, no. 1/3, 1985 Elsevier Biomedical Press, (Amsterdam, NL) F. Pasleau et al.: "Growth hormone gene expression in eukaryotic cells directed by the Rous sarcoma virus long terminal repeat or cytomegalovirus immediate- early promoter"; pages 227-232; see page 228, second column --	1-9	X	Journal of Virology, vol. 56, no. 1, October 1985 American Society for Microbiology (US) R.R. Spaete et al.: "Regulation of cytomegalovirus gene expression: α and β	1-9
Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³															
X	EP, A, 0173177 (BEHRINGWERKE AG) 5 March 1986 see the whole document --	1-9															
X	EP, A, 0173552 (THE UPJOHN CO.) 5 March 1986 see page 9, line 25 - page 10, line 2 --	1-9															
X	Gene, vol. 38, no. 1/3, 1985 Elsevier Biomedical Press, (Amsterdam, NL) F. Pasleau et al.: "Growth hormone gene expression in eukaryotic cells directed by the Rous sarcoma virus long terminal repeat or cytomegalovirus immediate- early promoter"; pages 227-232; see page 228, second column --	1-9															
X	Journal of Virology, vol. 56, no. 1, October 1985 American Society for Microbiology (US) R.R. Spaete et al.: "Regulation of cytomegalovirus gene expression: α and β	1-9															
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"Z" document member of the same patent family</p> </div> </div>																	
IV. CERTIFICATION <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">Date of the Actual Completion of the International Search</td> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">Date of Mailing of this International Search Report</td> </tr> <tr> <td style="border-bottom: 1px solid black; padding: 5px;">26th October 1988</td> <td style="border-bottom: 1px solid black; padding: 5px; text-align: right;">28 NOV 1988</td> </tr> <tr> <td style="border-bottom: 1px solid black; padding: 5px;">International Searching Authority</td> <td style="border-bottom: 1px solid black; padding: 5px;">Signature of Authorized Officer</td> </tr> <tr> <td style="padding: 5px; text-align: center;">EUROPEAN PATENT OFFICE</td> <td style="padding: 5px; text-align: right;"> P.C.G. VAN DER PUTTEN </td> </tr> </table>			Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	26th October 1988	28 NOV 1988	International Searching Authority	Signature of Authorized Officer	EUROPEAN PATENT OFFICE	 P.C.G. VAN DER PUTTEN							
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report																
26th October 1988	28 NOV 1988																
International Searching Authority	Signature of Authorized Officer																
EUROPEAN PATENT OFFICE	 P.C.G. VAN DER PUTTEN																

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
	promoters are trans activated by viral functions in permissive human fibroblasts", pages 135-143 see page 136, last five lines and first paragraph of page 137 (cited in the application) --	
X,P	EP, A, 0260148 (GENENTECH INC.) 16 March 1988, see page 9 (cited in the application) -----	1-9

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

GB 8800602

SA 23469

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 09/11/88. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0173177	05-03-86	DE-A- 3431140	06-03-86
		AU-A- 4660785	27-02-86
		JP-A- 61111692	29-05-86
EP-A- 0173552	05-03-86	JP-A- 61119192	06-06-86
EP-A- 0260148	16-03-88	FR-A- 2603899	18-03-88
		GB-A- 2197321	18-05-88
		AU-A- 7831787	19-05-88
		JP-A- 63152986	25-06-88
		DE-A- 3730599	07-07-88

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.